A Phase 4 interventional study of methotrexate and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 54 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-13.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 39th largest by enrollment, is one of 7 that started in 2011, is one of 38 in phase 4, and was the 57th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 47th largest by enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2011, is one of 28 in phase 4, and was the 117th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with rheumatoid arthritis and an inadequate response to methotrexate. All patients will receive RoActemra/Actemra 8 mg/kg intravenously (iv) every 4 weeks plus oral methotrexate for 16 weeks. Patients achieving low disease activity at Week 16 will be randomized to receive a further 12 weeks of RoActemra/Actemra treatment plus either methotrexate or placebo. Anticipated time on study treatment is 28 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]
Drug: methotrexate · Drug: placebo · Drug: tocilizumab [RoActemra/Actemra]
orally, Week 1 - 16
orally, Week 17-28
methotrexate placebo orally, Week 17-28
Drug page: Tocilizumab
8 mg/kg iv every 4 weeks, 28 weeks
Change in Disease Activity Score Based on 28-Joint Count (DAS28) From Week 16 to Week 28
The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (erythrocyte sedimentation rate \[ESR\] in millimeters per hour \[mm/hr\]), and general health status (participant global assessment of disease activity using visual analog scale \[VAS\], range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Baseline, Week 16, and Week 28
Percentage of Participants With DAS28 Score Less Than (<) 2.6 at Week 28
The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission.
Time frame: Week 28
Percentage of Participants With Clinical Disease Activity Index (CDAI) <2.8 at Week 28
CDAI is the sum of tender and swollen joint count based on 28 joints and the participant and physician global disease assessment (VAS 0-10 centimeters \[cm\]). CDAI total score 0-76; higher scores = greater affect due to disease activity. CDAI \<2.8 = clinical remission.
Time frame: Week 28
Percentage of Participants With Simplified Disease Activity Index (SDAI) <3.3 at Week 28
SDAI is calculated by a simple numerical sum of tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity (VAS 0-10 cm), and level of C-reactive protein in milligram per deciliter (mg/dL). SDAI total score 0-86; higher scores = greater affect due to disease activity. SDAI \<3.3 = clinical remission.
Time frame: 28 weeks
Change in the Health Assessment Questionnaire Disability Index (HAQ-DI) From Week 16 to Week 28
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Week 16 and Week 28
Change in the Quality of Life Questionnaire (Short Form-12 [SF-12]) From Week 16 to Week 28 in Mental Health
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. A negative change from baseline indicated decline in health and higher scores indicated improvement in health.
Time frame: Week 16 and Week 28
Change in the Quality of Life Questionnaire (SF-12) From Week 16 to Week 28 in Physical Health
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. A negative change from baseline indicated a worsening of quality of life.
Time frame: Week 16 and Week 28
Change From Week 16 to Week 28 in Global Assessment of Disease Activity as Assessed With the Visual Analogue Scale (VAS) Performed by Participant
Participants were asked to rate their global assessment of disease activity on a scale ranging from 0=very good to 100=very bad. The scale was represented by a line with 0 at the left edge and 100 at the right edge. The participant was asked to mark the line corresponding to the assessment of their disease activity. The distance from the left edge was measured in mm.
Time frame: Week 16 and Week 28
Change From Week 16 to Week 28 in Global Assessment of Disease Activity Assessed Using the VAS Performed by the Investigator
Participants were asked to rate their global assessment of disease activity on a scale ranging from 0=very good to 100=very bad. The scale was represented by a line with 0 at the left edge and 100 at the right edge. The participant was asked to mark the line corresponding to the assessment of their disease activity. The distance from the left edge was measured in mm.
Time frame: Week 16 and Week 28
| Milestone | Tocilizumab (TCZ) Plus (+) Methotrexate (Not Randomized) | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|---|
| Started | 96 | 83 | 82 |
| Completed | 55 | 80 | 78 |
| Not completed | 41 | 3 | 4 |
| Withdrew: Adverse event | 13 | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 0 | 0 |
| Withdrew: Investigator decisión | 1 | 0 | 2 |
| Withdrew: Lack of efficacy | 9 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Non-compliant | 1 | 0 | 0 |
| Withdrew: Inclusion error | 2 | 0 | 0 |
| Withdrew: Positive result for hepatitis b | 1 | 0 | 0 |
| Withdrew: Clinical ra remission | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (erythrocyte sedimentation rate \[ESR\] in millimeters per hour \[mm/hr\]), and general health status (participant global assessment of disease activity using visual analog scale \[VAS\], range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| units on a scale | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Baseline | 5.42 ± 1.01 | 5.29 ± 1.01 |
| Week 16 | 1.77 ± 0.77 | 1.96 ± 0.76 |
| Week 28 | 1.82 ± 1.18 | 1.98 ± 1.13 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission.
| percentage of participants | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Percentage of Participants With DAS28 Score Less Than (<) 2.6 at Week 28 | 82.3 | 75.9 |
CDAI is the sum of tender and swollen joint count based on 28 joints and the participant and physician global disease assessment (VAS 0-10 centimeters \[cm\]). CDAI total score 0-76; higher scores = greater affect due to disease activity. CDAI \<2.8 = clinical remission.
| percentage of participants | Tocilizumab + Methotrexate (Randomized) | Tocilizumab + Placebo (Randomized) |
|---|---|---|
| Percentage of Participants With Clinical Disease Activity Index (CDAI) <2.8 at Week 28 | 40.7 | 35.8 |
SDAI is calculated by a simple numerical sum of tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity (VAS 0-10 cm), and level of C-reactive protein in milligram per deciliter (mg/dL). SDAI total score 0-86; higher scores = greater affect due to disease activity. SDAI \<3.3 = clinical remission.
| percentage of participants | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Percentage of Participants With Simplified Disease Activity Index (SDAI) <3.3 at Week 28 | 35.1 | 28.2 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| units on a scale | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Change in the Health Assessment Questionnaire Disability Index (HAQ-DI) From Week 16 to Week 28 | 0.08 ± 0.47 | 0.00 ± 0.52 |
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. A negative change from baseline indicated decline in health and higher scores indicated improvement in health.
| units on a scale | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Change in the Quality of Life Questionnaire (Short Form-12 [SF-12]) From Week 16 to Week 28 in Mental Health | -2.36 ± 10.22 | -0.38 ± 9.25 |
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. A negative change from baseline indicated a worsening of quality of life.
| units on a scale | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Change in the Quality of Life Questionnaire (SF-12) From Week 16 to Week 28 in Physical Health | 0.48 ± 9.49 | -2.26 ± 8.82 |
Participants were asked to rate their global assessment of disease activity on a scale ranging from 0=very good to 100=very bad. The scale was represented by a line with 0 at the left edge and 100 at the right edge. The participant was asked to mark the line corresponding to the assessment of their disease activity. The distance from the left edge was measured in mm.
| units on a scale | TCZ + MTX (Randomized) | Tocilizumab + Placebo (Randomized) |
|---|---|---|
| Change From Week 16 to Week 28 in Global Assessment of Disease Activity as Assessed With the Visual Analogue Scale (VAS) Performed by Participant | 1.68 ± 23.80 | 0.56 ± 20.42 |
Participants were asked to rate their global assessment of disease activity on a scale ranging from 0=very good to 100=very bad. The scale was represented by a line with 0 at the left edge and 100 at the right edge. The participant was asked to mark the line corresponding to the assessment of their disease activity. The distance from the left edge was measured in mm.
| units on a scale | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) |
|---|---|---|
| Change From Week 16 to Week 28 in Global Assessment of Disease Activity Assessed Using the VAS Performed by the Investigator | 2.71 ± 16.96 | 2.85 ± 18.48 |
Collected over From Day 1 up to Week 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TCZ + MTX (Not Randomized) | — | 11/96 (11.5%) | 28/96 (29.2%) |
| TCZ + MTX (Pre-randomization) | — | 0/83 (0%) | 20/83 (24.1%) |
| TCZ + Placebo (Pre-randomization) | — | 1/82 (1.2%) | 24/82 (29.3%) |
| TCZ + MTX (Post-randomization) | — | 1/83 (1.2%) | 8/83 (9.6%) |
| TCZ + Placebo (Post-randomization) | — | 4/82 (4.9%) | 4/82 (4.9%) |
| Event | TCZ + MTX (Not Randomized) | TCZ + MTX (Pre-randomization) | TCZ + Placebo (Pre-randomization) | TCZ + MTX (Post-randomization) | TCZ + Placebo (Post-randomization) |
|---|---|---|---|---|---|
| HypertransaminasaemiaHepatobiliary disorders | 3/96 | 0/83 | 0/82 | 0/83 | 0/82 |
| Deep vein thrombosisVascular disorders | 2/96 | 0/83 | 0/82 | 0/83 | 0/82 |
| VertigoEar and labyrinth disorders | 0/96 | 0/83 | 0/82 | 0/83 | 1/82 |
| Bursitis infectiveInfections and infestations | 0/96 | 0/83 | 0/82 | 0/83 | 1/82 |
| PneumoniaInfections and infestations | 1/96 | 0/83 | 0/82 | 0/83 | 1/82 |
| Staphylococcal skin infectionInfections and infestations | 0/96 | 0/83 | 0/82 | 0/83 | 1/82 |
| Respiratory tract infectionInfections and infestations | 0/96 | 0/83 | 1/82 | 0/83 | 0/82 |
| Endocarditis bacterialInfections and infestations | 0/96 | 0/83 | 0/82 | 1/83 | 0/82 |
| Chest PainGeneral disorders | 1/96 | 0/83 | 0/82 | 0/83 | 0/82 |
| Cytomegalovirus infectionInfections and infestations | 1/96 | 0/83 | 0/82 | 0/83 | 0/82 |
| Event | TCZ + MTX (Not Randomized) | TCZ + MTX (Pre-randomization) | TCZ + Placebo (Pre-randomization) | TCZ + MTX (Post-randomization) | TCZ + Placebo (Post-randomization) |
|---|---|---|---|---|---|
| HypertransaminasaemiaHepatobiliary disorders | 15/96 | 12/83 | 10/82 | 8/83 | 4/82 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 9/96 | 2/83 | 6/82 | 0/83 | 0/82 |
| Aphthous stomatitisGastrointestinal disorders | 0/96 | 3/83 | 6/82 | 0/83 | 0/82 |
| LeukopeniaBlood and lymphatic system disorders | 7/96 | 0/83 | 0/82 | 0/83 | 0/82 |
| NeutropeniaBlood and lymphatic system disorders | 7/96 | 0/83 | 0/82 | 0/83 | 0/82 |
| Urinary tract infectionInfections and infestations | 0/96 | 3/83 | 5/82 | 0/83 | 0/82 |
| Respiratory tract infectionInfections and infestations | 5/96 | 0/83 | 0/82 | 0/83 | 0/82 |
All treated population
| Age, Continuous(years) | TCZ + MTX (Not Randomized) | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) | Total |
|---|---|---|---|---|
| Mean | 52.3 ± 13.2 | 50.2 ± 12.5 | 51.0 ± 12.2 | 51.2 ± 12.6 |
| Sex: Female, Male(Participants) | TCZ + MTX (Not Randomized) | TCZ + MTX (Randomized) | TCZ + Placebo (Randomized) | Total |
|---|---|---|---|---|
| Female | 76 | 62 | 65 | 203 |
| Male | 20 | 21 | 17 | 58 |
The record gives a start of Sep 2011, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Tocilizumab